Category: Uncategorized

Ermium receives 800 000 € from Bpifrance, the French Innovation agency

Ermium receives 800 000 € from Bpifrance, the French Innovation agency

Ermium has been granted 800 000 € as “aide à l’innovation” (Innovation support) from Bpifrance, the French agency for innovation, to further advance its therapeutic approach for auto-immune diseases including systemic lupus erythematosus, Sjögren’s syndrome and other type I interferon driven diseases

Share

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M to further advance breakthrough auto-immune disease therapeutics.

Share

Formation of a Scientific Advisory Board

Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr Hélène Asnagli as Head of Biology/Pharmacology. Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.

Annegret Van der Aa, PhD joins Ermium Therapeutics

Laurent Audoly, PhD, President and CEO of Parthenon Therapeutics, as non executive director of Ermium Therapeutics

Laurent Audoly is a pharma and biotech entrepreneur and senior executive. He is co-founder, CEO and Chairman of Parthenon Therapeutics, and has also led corporate and R&D functions across both pharma and biotech in the US and Europe, particularly in the field of auto-immune diseases, including as CEO of Kymera Therapeutics and Head of R&D at Pierre Fabre Pharmaceuticals, as well as scientific and business leadership positions at Pfizer, Merck and Pieris.